RDY:NYSE
瑞迪制药
US$13.73
arrow_downward
-2.14%(-0.30) 1 天
US$13.73
0.00% (0.00)
bedtime盘后交易
休市： 4月29日, GMT-4 16:00:03 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 RDY 生成关键数据洞见…
开盘价
US$13.84
最高价
US$13.95
最低价
US$13.68
市值
一一七.一九亿
平均成交量
二三一.九五万
成交量
九.〇〇
股息
〇.六七%
季度股息
US$0.02
除息日
2024年7月16日
市盈率
一九.一二
52 周最高价
US$16.17
52 周最低价
US$12.77
每股收益
US$0.72
Beta 版
〇.三七
流通股数
八.三五亿
员工人数
三万
新闻报道
来自全网
Yahoo Finance
·
16小时前
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
Stock Titan
·
21小时前
Dr. Reddy’s (NYSE: RDY) first with generic Semaglutide Injection approval in Canada
Business Standard
·
1天前
Canada approves DRL's Ozempic generic after months of regulatory logjam
资料
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
瑞迪制药简介